US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy - Reuters
reuters.comSubmitted by reuters8361 in health
Some leading U.S. obesity specialists say they expect Eli Lilly’s <a href="https://www.reuters.com/markets/companies/LLY.N" target="_blank">(LLY.N)</a> powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s <a hre…